Health Alert in Rajasthan: 7 Drug Batches Fail Quality Tests, Banned

The CSR Journal Magazine

Concerned about public health and safety, the Commissionerate of Food Safety and Drug Control, Rajasthan, issued an urgent alert: 7 medicines have been tested and declared ‘Not of Standard Quality’. These medicines were tested in labs between April 1 and April 15, 2026 and shocking finding came up, after which the regulatory action was taken. Post the results, the Drug Controller issued direction to all the Drug Control Officers to withdraw the identified batches at the earliest.

The Commissioner of Food Safety and Drug Control, Rajasthan, Dr. T. Shubhamangala said the media that the department keeps on testing for quality surveillance and make sure that safe medicines reach the common man. And similarly this latest batch was tested for safety and it was noted that the products failed to meet prescribed quality standards, raising serious concerns.

Drugs that has been banned immediately

1.     Cefixime Oral Suspension (LORAXIM Dry Syrup), Batch LXS3-49 (Expiry October 2026), made by Lark Laboratories, Bhiwadi, failed to meet the standards for its active ingredient.

2.      Albendazole Tablets, Batch PG124427 (Expiry June 2027), made by Affy Parenterals, Baddi, failed the dissolution test.

3.     Istocuf-LS Drops (Ambroxol, Levosalbutamol, Guaiphenesin), Batch GLF0712B (Expiry June 2027), made by Digital Vision, Kala Amb.

4.     Methylprednisolone Tablets (Methyloactive-4), Batch 252005 (Expiry June 2027), manufactured by United Bioceuticals, Haridwar.

5.     Okuff-DX Syrup (Dextromethorphan and Chlorpheniramine), Batch TLLM-188 (Expiry November 2026), manufactured by Taksa Lifesciences.

6.     Cefuroxime Tablets (EXTENSIVE-500), Batch VT252942 (Expiry February 2028), manufactured by VADSP Pharmaceuticals, Baddi.

7.      Ciprofloxacin Tablets 500 mg, Batch GT50135 (Expiry April 2028), manufactured by Omega Pharma, Roorkee.

Both government and private hospitals have been instructed by the Drug Controller Ajay Phatak to immediately stop the distribution, sale, and use of these medicines. In the order it has been mentioned that if new batches are ordered from the listed manufacturers then it has to undergo comprehensive quality checks. And the order further noted that strict action would be taken under the Drugs and Cosmetics Act and related regulatory provisions if any violation occurred.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share

Latest News

Popular Videos